Type 2 Diabetes Mellitus and Nonvalvular Atrial Fibrillation in Mexico: National Registries Raise a Red Flag.

Autor: Márquez-Murillo MF; Department of Cardiology, Centro Médico ABC, Mexico City, Mexico., Brenner-Muslera E; School of Medicine, Universidad Panamericana, Mexico City, Mexico., Rodríguez-Carrillo DL; Department of Cardiology, Centro Médico ABC, Mexico City, Mexico., Chua-López CA; Department of Cardiology, Centro Médico ABC, Mexico City, Mexico., Torres-Tamayo M; Sociedad Mexicana de Nutrición y Endocrinología, Mexico City, Mexico.
Jazyk: angličtina
Zdroj: Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion [Rev Invest Clin] 2023; Vol. 75 (4), pp. 179-186.
DOI: 10.24875/RIC.23000056
Abstrakt: Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide and is highly prevalent in Mexico, as 10.2% of the adult population harbors this condition. T2DM is usually associated with cardiovascular comorbidities, including arrhythmias. Metabolic impairment is one of the mechanisms that contribute to tissue remodeling that affects atrial structure, and concomitant, the cardiac conduction system, both could result in atrial fibrillation (AF). AF is estimated to affect more than a half million Mexicans, and its incidence is expected to keep rising. According to national registries, T2DM is present in 28.4% of Mexican patients with AF and the coexistence of both diseases is associated with a higher risk of stroke. In clinical practice, the CHA 2 DS 2 -VASc risk score is useful for stroke risk stratification in patients with AF to facilitate the adequate use of anticoagulation therapy. T2DM is among the items of the CHA 2 DS 2 -VASc score because it correlates with an intrinsic prothrombotic state. In this narrative review, we present information that highlights the need for optimal glucose control and adequate anticoagulation in subjects with T2DM and AF.
(Copyright: © 2023 Permanyer.)
Databáze: MEDLINE
Externí odkaz: